Phage therapy targeting Escherichia coli-a story with no end?

FEMS Microbiology Letters

Volumn 363, Issue 22, 2016, Pages

  Bolocan, Andrei Sorin ^a   Callanan, Julie ^a   Forde, Amanda ^a   Ross, Paul ^a   Hill, Colin ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

AIEC; Phage therapy; STEAEC; UTI

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; BIOFILM; CAUDOVIRALES; COLIPHAGE; CROHN DISEASE; DIARRHEA; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI PNEUMONIA; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; HUMAN; INFLAMMATORY BOWEL DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; PHAGE THERAPY; SEPTICEMIA; SHORT SURVEY; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VENTILATOR ASSOCIATED PNEUMONIA; FOOD POISONING; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PROCEDURES; VIROLOGY;

COLIPHAGES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOODBORNE DISEASES; HUMANS; PHAGE THERAPY;

EID: 85014954585     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnw256     Document Type: Short Survey

References (50)

1. Agus A, Massier S, Darfeuille-Michaud A et al. Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. Biomed Res Int 2014;2014:567929.
2. Beke G, Stano M, Klucar L. Modelling the interaction between bacteriophages and their bacterial hosts. Math Biosci 2016;279:27-32.
3. Brüssow H. Phage therapy: The Escherichia coli experience. Microbiology 2005;151:2133-40.
4. Cabal A, García-Castillo M, Cantón R et al. Prevalence of Escherichia coli virulence genes in patients with diarrhea and a subpopulation of healthy volunteers in Madrid, Spain. Front Microbiol 2016;7:1-6.
5. Cao F, Wang X, Wang L et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int 2015;2015:752930.
6. Chadha P, Katare OP, Chhibber S. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog 2016;99:68-77.
7. Chibeu A, Lingohr EJ, Masson L et al. Bacteriophages with the ability to degrade uropathogenic Escherichia Coli biofilms. Viruses 2012;4:471-87.
8. Clements A, Young JC, Constantinou N et al. Infection strategies of enteric pathogenic Escherichia coli. Gut Microbes 2012;3: 71-87.
9. Clokie MRJ, Kropinski A. Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions. Clokie MRJ, Kropinski A (ed.), New Delhi: Human Press, 2009.
10. Conte MP, Longhi C, Marazzato M et al. Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features. BMC Res Notes 2014;7:748.
11. da Silva Santos AC, Gomes Romeiro F, Yukie Sassaki L et al. Escherichia coli from Crohn's disease patient displays virulence features of enteroinvasive (EIEC), enterohemorragic (EHEC), and enteroaggregative (EAEC) pathotypes. Gut Pathog 2015;7:2.
12. Dalmasso M, de Haas E, Neve H et al. Isolation of a novel phage with activity against Streptococcus mutans biofilms. PLoS One 2015;10:e0138651.
13. Dalmasso M, Strain R, Neve H et al. Three new Escherichia coli phages from the human gut show promising potential for phage therapy. PLoS One 2016;11:e0156773.
14. Danglas P, Debarbieux L. Bacteriophage Therapy-WO2014177622A1, Misc. Google Patents, 2014.
15. Dufour N, Clermont O, La Combe B et al. Bacteriophage LM33 P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. J Antimicrob Chemoth 2016;71:3072-80.
16. Dufour N, Debarbieux L, Fromentin M et al. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 2015;43: e190-8.
17. Dulai PS, Levesque BG, Feagan BG et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55.
18. Eun CS, Mishima Y, Wohlgemuth S et al. Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10(-/-) mice. McCormick BA (ed.). Infect Immun 2014;82:2239-46.
19. Galtie M, De Sordi L, Maura D et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol 2016;18:2237-45.
20. Glasser A-L, Boudeau J, Barnich N et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001;69:5529-37.
21. Hasman H, Hammerum AM, Hansen F et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat, Denmark 2015. Eurosurveillance Online Ed 2015;20:1-5.
22. Jamalludeen N, She Y-M, Lingohr EJ et al. Isolation and characterization of virulent bacteriophages against Escherichia coli serogroups O1, O2, and O78. Poult Sci 2009;88:1694-702.
23. Jin D, Zhang H, Sun J. Manipulation of microbiome, a promising therapy for inflammatory bowel diseases. J Clin Cell Immunol 2014;5:1-10.
24. Kakkanat A, Totsika M, Schaale K et al. The role of H4 flagella in Escherichia coli ST131 virulence. Sci Rep 2015;5:16149.
25. Keen EC. A century of phage research: Bacteriophages and the shaping of modern biology. BioEssays 2015;37:6-9.
26. Khan Mirzaei M, Nilsson AS. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One 2015;10:e0118557.
27. Kysela DT, Turner PE. Optimal bacteriophage mutation rates for phage therapy. J Theor Biol 2007;249:411-21.
28. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 2016; 8:39.
29. Lynch JP, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum ß-lactamases and carbapenemases). Expert Opin Pharmaco 2013;14:199-210.
30. Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Cl Lab Sci 2009;46: 25-54.
31. Melo LDR, Veiga P, Cerca N et al. Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections. Front Microbiol 2016;7:1-12.
32. Messika J, Magdoud F, Clermont O et al. Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains. Intensive Care Med 2012;38:2007-16.
33. Millar MR, Seale J, Turton J et al. Prevalence of Escherichia coli virulence genes in patients with diarrhea and a subpopulation of healthy volunteers in Madrid, Spain. Front Microbiol 2016;7:1174-7.
34. Mora A, Herrera A, López C et al. Characteristics of the Shigatoxin-producing enteroaggregative Escherichia coli O104: H4 German outbreak strain and of STEC strains isolated in Spain. Int Microbiol 2011;14:121-41.
35. Naser SA, Sagramsingh SR, Naser AS et al. Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients. World J Gastroenterol 2014;20:7403-15.
36. Niu YD, McAllister TA, Nash JHE et al. Four Escherichia coli O157:H7 phages: a new bacteriophage genus and taxonomic classification of T1-like phages. PLoS One 2014;9:e100426.
37. O'Brien CL, Bringer M-A, Holt KE et al. Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli. Gut 2016;0:1-8.
38. Perepanova TS, Darbeeva OS, Kotliarova GA et al. The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol Nefrol 1994;5:14-7.
39. Pouillot F, Chomton M, Blois H et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTXM-15. Antimicrob Agents Ch 2012;56:3568-75.
40. Sarker SA, Sultana S, Reuteler G et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 2015;4:124-37.
41. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 2012;1:15-21.
42. Sheng H, Knecht HJ, Kudva IT et al. Application of bacteriophages to control intestinal Escherichia coli O157: H7 levels in ruminants. Appl Environ Microb 2006;72:5359-66.
43. Snyder AB, Perry JJ, Yousef AE. Developing and optimizing bacteriophage treatment to control enterohemorrhagic Escherichia coli on fresh produce. Int J Food Microbiol 2016;236:90-7.
44. Song B, Xiong H, Xu Y et al. Isolation of a novel polyvalent virulent bacteriophage of E. coli. J Med Coll PLA 2007;22: 261-7.
45. Soto SM. Importance of biofilms in urinary tract infections: new therapeutic approaches. Adv Biol 2014;2014: 1-13.
46. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Ch 2001;45:649-59.
47. Sybesma W, Zbinden R, Chanishvili N et al. Bacteriophages as potential treatment for urinary tract infections. Front Microbiol 2016;7:1-9.
48. Tomat D, Mercanti D, Balagu C et al. Phage biocontrol of enteropathogenic and shiga toxin-producing Escherichia coli during milk fermentation. Lett Appl Microbiol 2013;57: 3-10.
49. Tsui J, Jacobs J, Braun J. Bacteriophages as a therapeutic strategy to target adherent, invasive Escherichia coli associated with inflammatory bowel disease. 2014 SACNAS National Conference. Research Presentation FRI-1130. Madison, USA: Omnipress, 2014.
50. Zhang L. Oral Campylobacter species: initiators of a subgroup of inflammatory bowel disease? World J Gastroenterol 2015;21:9239-44.